Six arrested, dozens investigated over use of toxic paint to brighten food in China kindergarten
An official investigation released on Sunday found severe failures in oversight, food safety, and attempts to cover up the incident, including bribery and falsification of test results, The Guardian reported.
The principal of Brownstone Peixin Kindergarten in Tianshui allegedly sought to attract more enrolments by making food look more appealing using non-edible pigment bought online.
Despite clear warnings that the pigment was 'not for consumption,' the school's cook added it to children's meals, preferring its 'brighter' hues to safer, cheaper food-grade alternatives.
One pigment used in the food contained lead levels that exceeded legal limits by 400,000 times, according to the Gansu provincial party committee report.
Initially, 235 children were hospitalised after consuming the tainted food, showing symptoms including nausea, stomach pain, and discoloured teeth, with later tests confirming 247 people had elevated blood lead levels.
Six kindergarten staff, including the principal, now face criminal charges for knowingly serving toxic food, while 27 others from the school, hospital and government are under disciplinary review.
The report also revealed that the Gansu Provincial Centre for Disease Control mishandled the case and conducted tests improperly, leading to results that did not reflect actual exposure.
At least two test results at Tianshui Second People's Hospital were deliberately altered to show falsely low lead levels, while the hospital was described as poorly managed and lacking proper training.
Parents reportedly protested outside the kindergarten on Sunday night, clashing with police and demanding accountability, as authorities promised further investigations into corruption, misconduct, and regulatory failures at every level.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
2 days ago
- Malay Mail
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
HONG KONG SAR - Media OutReach Newswire - 25 July 2025 – MicroPort Scientific Corporation (Stock Code: "MicroPort") announced that Shanghai Healthcare M&A Fund ("SHMAF"), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical #SIICCapital #MicroPort #SHMAF The issuer is solely responsible for the content of this announcement. About MicroPort Scientific Corporation Founded in 1998 and headquartered in Shanghai's Zhangjiang, MicroPort Scientific Corporation is a leading domestic innovative high-end medical device group. It began by breaking the import monopoly in the cardiovascular stent field, and after 26 years of innovative development, its business has expanded to areas including rhythm management, orthopaedics, cardiovascular intervention, aortic and peripheral vascular intervention, neurovascular intervention, heart valves, surgical robots, and surgical medical devices. By the end of 2024, MicroPort operated in over 20,000 hospitals across 100 countries and regions worldwide, providing more than 600 solutions for patients covering over 200 diseases. MicroPort has incubated 6 A-share and Hong Kong-listed companies, owns 9 specialized and sophisticated SMEs, 4 technology giant enterprises, and 16 national high-tech enterprises, making it an outstanding representative of Shanghai's technological innovation and industrial transformation. About SIIC Capital As the active fund management platform under SIIC Group, since its establishment, SIIC Capital has been based in Shanghai, connected with Hong Kong, and oriented towards the world, actively exploring investment opportunities in strategic emerging industries such as biomedicine and green environmental protection. Through a multi-currency, full-stage fund matrix layout, it deeply serves national strategies and the construction of biomedicine highlands.
Malay Mail
5 days ago
- Malay Mail
Six arrested, dozens investigated over use of toxic paint to brighten food in China kindergarten
BEIJING, July 22 — Chinese authorities have arrested six people and are investigating 27 others after more than 230 children at a kindergarten in Gansu province were poisoned by food coloured with industrial-grade lead paint. An official investigation released on Sunday found severe failures in oversight, food safety, and attempts to cover up the incident, including bribery and falsification of test results, The Guardian reported. The principal of Brownstone Peixin Kindergarten in Tianshui allegedly sought to attract more enrolments by making food look more appealing using non-edible pigment bought online. Despite clear warnings that the pigment was 'not for consumption,' the school's cook added it to children's meals, preferring its 'brighter' hues to safer, cheaper food-grade alternatives. One pigment used in the food contained lead levels that exceeded legal limits by 400,000 times, according to the Gansu provincial party committee report. Initially, 235 children were hospitalised after consuming the tainted food, showing symptoms including nausea, stomach pain, and discoloured teeth, with later tests confirming 247 people had elevated blood lead levels. Six kindergarten staff, including the principal, now face criminal charges for knowingly serving toxic food, while 27 others from the school, hospital and government are under disciplinary review. The report also revealed that the Gansu Provincial Centre for Disease Control mishandled the case and conducted tests improperly, leading to results that did not reflect actual exposure. At least two test results at Tianshui Second People's Hospital were deliberately altered to show falsely low lead levels, while the hospital was described as poorly managed and lacking proper training. Parents reportedly protested outside the kindergarten on Sunday night, clashing with police and demanding accountability, as authorities promised further investigations into corruption, misconduct, and regulatory failures at every level.
Malay Mail
6 days ago
- Malay Mail
Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem
Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological HONG KONG SAR - Media OutReach Newswire - 21 July 2025 - Chengdu Kanghua Biological Products Co., Ltd. (Stock Code: announced that Shanghai Healthcare M&A Fund ("the M&A Fund") intends to acquire the Company through a strategic agreement. Leveraging its substantial resource and financial strength, the M&A Fund plans to support Kanghua Biological's established product portfolio, accelerate sales of its mature products, and develop industry synergies between Shanghai and Chengdu. The goal is to rapidly expand a diversified vaccine pipeline and build an integrated vaccine ecosystem that combines proven commercialized products with best-in-class R&D vaccine industry is an essential pillar of public health with high entry barriers, stringent oversight, and extended development cycles – all factors contributing to its significant growth potential. As a leading domestic vaccine producer, Kanghua Biological's flagship product - human diploid cell rabies vaccine – stands as China's first domestically developed premium vaccine with over a decade of safe application, established market presence and nationwide distribution. The Company also maintains a robust global innovation pipeline, having successfully licensed its recombinant hexavalent norovirus vaccine overseas. This strategic acquisition, focused on critical segments of the vaccine value chain, will strengthen its strategic positioning. The M&A Fund is committed to supporting Kanghua Biological in leveraging its core product line while harnessing the combined strengthens of Shanghai and Chengdu to accelerate the formation of a next-generation vaccine industry acquisition marks a significant step to drive Shanghai and Chengdu biopharmaceutical cooperation. Post-transaction, Kanghua Biological will capitalize on Shanghai's advanced R&D resources and access to top-tier scientific talent and global capital to enhances its industrial capabilities, manufacturing capacity, and market penetration. The M&A Fund will consolidate diverse industrial assets to promote Kanghua Biological's integration with Shanghai's R&D and clinical networks, creating an end-to-end collaborative system that spans from "clinical R&D to commercialization" and accelerates the development of a full industrial value chain."This transaction goes beyond a typical corporate acquisition, it represents a transformative catalyst for industrial upgrading,""This exemplifies the complementary strengths created by resource-empowered consolidation. With deep biopharmaceutical, financial, R&D, and global network expertise, Shanghai Healthcare M&A Fund will create significant synergies with Kanghua Biological's technologies, products, manufacturing, and domestic distribution to have an outsized impact on the sector."Hashtag: #SIICCapital #ChengduKanghuaBiological #ShanghaiHealthcareM&AFund The issuer is solely responsible for the content of this announcement. About Shanghai Healthcare M&A Fund A core component of Shanghai's state-owned capital fund network, Shanghai Healthcare M&A Fund is managed by SIIC Capital, a subsidiary of SIIC Group. The M&A Fund targets Shanghai's biopharmaceutical sector, aligning government policy objectives with industrial needs by fostering collaboration with leading industry companies, strengthening sector clusters, and enabling asset restructuring. Through capital infusion, improving governance, optimizing management, and executing M&A, the M&A Fund backs "anchor" companies to build complementary and reinforcing links in the value chain, driving the ongoing transformation of specialized subsectors. About Chengdu Kanghua Biological Products Co., Ltd. Chengdu Kanghua Biological Products Co., Ltd. is a biopharmaceutical company engaged in research, manufacture and commercialization of biological products. Established in 2004, the company operates an in-house testing center and GMP-certified bacterial and viral vaccine production facilities. Its marketed portfolio includes the ACYW135 meningococcal polysaccharide vaccine and a freeze-dried human diploid cell rabies vaccine. Kanghua holds GMP certification from China's National Medical Products Administration, has participated in numerous scientific research projects and has been granted patents for over 100 technologies.
